A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2'fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF(165) aptamer binds specifically to the VEGF(165) isoform, a dimeric protein with a receptor-binding domain and a heparin-binding domain (HBD). To understand the molecular recognition between VEGF and this aptamer, binding experiments were used to show that the HBD contributes the majority of binding energy in the VEGF(165)-aptamer complex. A tissue culture-based competition assay demonstrated that the HBD effectively competes with VEGF(165) for aptamer binding in vivo. Comparison of NMR spectra revealed that structural features of the smaller HBD-aptamer complex are present in the full-length VEGF(164)-aptamer complex. These data show that the HBD provides the binding site for the aptamer and is the primary determinant for the affinity and specificity in the VEGF(165)-aptamer complex.

[1]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[2]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[3]  David G. Gorenstein,et al.  Phosphorus-31 NMR : principles and applications , 1984 .

[4]  I. Bernard-Pierrot,et al.  Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.

[5]  R. Shulman,et al.  31P magnetic resonance of tRNA. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Williamson.  Induced fit in RNA–protein recognition , 2000, Nature Structural Biology.

[7]  Anthony D. Keefe,et al.  Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. , 2005, Chemistry & biology.

[8]  M. Willis,et al.  Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. , 2000, Journal of biotechnology.

[9]  D. Patel,et al.  Adaptive recognition by nucleic acid aptamers. , 2000, Science.

[10]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[11]  R. Riek,et al.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[13]  N. Skelton,et al.  Refinement of the solution structure of the heparin-binding domain of vascular endothelial growth factor using residual dipolar couplings , 2002, Journal of biomolecular NMR.

[14]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[15]  F. Gruber,et al.  NAB2, a Corepressor of EGR-1, Inhibits Vascular Endothelial Growth Factor-mediated Gene Induction and Angiogenic Responses of Endothelial Cells* , 2003, The Journal of Biological Chemistry.

[16]  A. Gronenborn,et al.  31P NMR analysis of the DNA conformation induced by protein binding SRY/DNA complexes. , 2000, European journal of biochemistry.

[17]  Charles Eigenbrot,et al.  Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor , 1997, Cell.

[18]  N. Janjić,et al.  Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. , 1994, Biochemistry.

[19]  E. Ng,et al.  Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[20]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[21]  N. Janjić,et al.  Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro , 1999, In Vitro Cellular & Developmental Biology - Animal.

[22]  M. Iruela-Arispe,et al.  ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.

[23]  A. Schachat.  New treatments for age-related macular degeneration. , 2005, Ophthalmology.

[24]  Joan W. Miller,et al.  VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.

[25]  T. Shiomi,et al.  Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  K. Constantine,et al.  Localizing the NADP+ binding site on the MurB enzyme by NMR , 1996, Nature Structural Biology.

[27]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[28]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[29]  B. J. Limberg,et al.  Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 * , 2001, The Journal of Biological Chemistry.

[30]  K. Alitalo,et al.  The biology of vascular endothelial growth factors. , 2005, Cardiovascular research.

[31]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[32]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.